IPO - Profile

Prometheus Biosciences, Inc.

Health Care > Major Pharmaceuticals

RXDX

Summary

We are a biotechnology company pioneering a precision medicine approach to the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). We leverage our proprietary precision medicine platform, Prometheus360™, which includes one of the world’s largest gastrointestinal (GI) bioinformatics databases, to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, we are developing companion diagnostic tests designed to identify patients more likely to respond to our therapeutic candidates. We have generated a robust pipeline of More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$19.00 10,000,000 Positive High 39.24%

Offering Team

  • Legal counsel
  • Latham & Watkins LLP
  • Auditors
  • BDO USA, LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 11 Mar, 2021

Offer 12 Mar, 2021

Look Ahead

Lock Up Expiry Sep 12, 2021

IPO Terms

Offer Price $19.00
Offer Size 10M

Market Sentiments

Stock Price